Publication | Open Access

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Surgical OncologyHealth SciencesGliomaMedicineSecond Interim AnalysisMetronomic TherapyNon-co-deleted Anaplastic GliomaHigh-grade GliomasCancer TreatmentOncologyRadiation OncologyCancer ResearchRadiologyConcurrent Temozolomide